Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

NCT05396118 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Neuroendocrine Tumors
Neuroendocrine Carcinoma
Neuroendocrine Carcinoma Metastatic
Lymphoma
Sarcoma

Interventions

DRUG: 18F-FDG
DRUG: Injection of hyperpolarized [1-13C]Pyruvate
PROCEDURE: PET/MR/MRS/MRSI scanning

Sponsor

Rigshospitalet, Denmark